Nothing Special   »   [go: up one dir, main page]

Eren et al., 2023 - Google Patents

Effects of autologous serum on TREM2 and APOE in a personalized monocyte-derived macrophage assay of late-onset Alzheimer's patients

Eren et al., 2023

View HTML @Full View
Document ID
14487743677160221351
Author
Eren N
Gerike S
Üsekes B
Peters O
Cosma N
Hellmann-Regen J
Publication year
Publication venue
Immunity & Ageing

External Links

Snippet

Background Age-associated deterioration of the immune system contributes to a chronic low- grade inflammatory state known as “inflammaging” and is implicated in the pathogenesis of late-onset Alzheimer's disease (LOAD). Whether changes in the tissue environment caused …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material

Similar Documents

Publication Publication Date Title
Kluge et al. Detection of neuron-derived pathological α-synuclein in blood
Gelpi et al. Neuropathological criteria of anti-IgLON5-related tauopathy
Farah et al. Salivary biomarkers for the diagnosis and monitoring of neurological diseases
Gao et al. Decreased levels of circulating trimethylamine N-oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimer’s disease
Mildner et al. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases
Kövesdi et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics
Brink et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions
Heinsinger et al. Apolipoprotein E genotype affects size of ApoE complexes in cerebrospinal fluid
Lashley et al. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies
Dutta et al. Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges
DeLuca et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology
Baba et al. Metabolism of amyloid-β protein may be affected in depression
Fei et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment
Cupidi et al. Refining the spectrum of neuronal intranuclear inclusion disease: a case report
Xu et al. Brain‐derived extracellular vesicles: Potential diagnostic biomarkers for central nervous system diseases
Vijverberg et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD
Ramos-Campoy et al. Systematic screening of ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation
Vinaiphat et al. Clinical implications of extracellular vesicles in neurodegenerative diseases
Adamo et al. White matter hyperintensities in burning mouth syndrome assessed according to the age-related white matter changes scale
Chung et al. Neuroinflammation upregulated neuronal toll-like receptors 2 and 4 to drive synucleinopathy in neurodegeneration
Sanchez-Sanchez et al. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults
Visconte et al. Plasma microglial-derived extracellular vesicles are increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect
Vaz et al. Extracellular vesicles in the study of Alzheimer's and Parkinson's diseases: Methodologies applied from cells to biofluids
Li et al. Distinct brain functional impairment patterns between suspected non-alzheimer disease pathophysiology and alzheimer’s disease: a study combining static and dynamic functional magnetic resonance imaging
Gong et al. Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?